Crispr-Cas Component Systems, Methods And Compositions For Sequence Manipulation

Patent No. EP2840140 (titled "Crispr-Cas Component Systems, Methods And Compositions For Sequence Manipulation") was filed by Massachusetts Institute OF Technology on Dec 12, 2013. The application was issued on Feb 22, 2023.

Patent Summary

This method selects prokaryotic cells by introducing specific mutations via recombination. Vectors are introduced to drive the expression of a Cas9 enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and an editing template. The editing template is recombined into a target polynucleotide, introducing mutations to the protospacer-adjacent motif (PAM) or protospacer sequence that abolish Cas9 cleavage. A CRISPR complex—comprising the Cas9 enzyme, the guide sequence hybridized to the target, and the tracr mate sequence hybridized to the tracr sequence—is allowed to bind the target polynucleotide. Cleavage of the target polynucleotide by the CRISPR complex induces cell death, thereby selectively isolating prokaryotic cells that successfully incorporated the mutations.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2840140

MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Application Number
EP14188820A
Filing Date
Dec 12, 2013
Status
Patent Maintained As Amended
Jan 20, 2023
Publication Date
Feb 22, 2023